NDAORALCAPSULE
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
CITALOPRAM HYDROBROMIDE (citalopram) by Almatica Pharma is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). Approved for major depressive disorder, generalized anxiety disorder. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Citalopram hydrobromide is an oral SSRI capsule approved in January 2022 by Almatica Pharma for major depressive disorder and generalized anxiety disorder. It works by inhibiting serotonin reuptake in the central nervous system, potentiating serotonergic activity. The mechanism is presumed but not fully elucidated.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30), indicating stable commercial team size but heightened focus on differentiation and market defense.
Mechanism of Action
unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Indications (2)
Worked on CITALOPRAM HYDROBROMIDE at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.